Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

NCT00778921 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

847

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Amlodipine 10 mg
DRUG: Aliskiren 150
DRUG: Amlodipine 300

Sponsor

Novartis